Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05059444 · ClinicalTrials.gov registry record
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
A clinical trial of Non-Small Cell Lung Cancer and Pancreatic Adenocarcinoma, sponsored by Guardant Health.
- Recruiting
- Registry status
- 2,020
- Enrollment target
- 20
- Study locations
NCT05059444 is a study of Non-Small Cell Lung Cancer and Pancreatic Adenocarcinoma that is actively recruiting participants, run by Guardant Health. The registered enrollment target is 2,020 participants, above the 654-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (209% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT05059444, a study of Non-Small Cell Lung Cancer and Pancreatic Adenocarcinoma, is actively recruiting participants, sponsored by Guardant Health.
- RECRUITING
- Registry status
- 2,020 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Guardant Reveal
Study Locations (20)
California
- University of California, San Diego - La Jolla
- Hoag Memorial Hospital Presbyterian - Newport Beach
- Redwood City - Redwood City
- Sutter Institute for Medical Research - Sacramento
Florida
- Memorial Healthcare System - Hollywood
- The Oncology Institute of Hope & Innovation - Lakeland
Louisiana
- Tulane Cancer Center - New Orleans
- Christus Highland/ Boniol - Shreveport
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Ironwood Cancer & Research Centers - Chandler
Arkansas
- Genesis Cancer Center - Hot Springs
Colorado
- University of Colorado - Aurora
Maine
- Central Maine Medical Center - Lewiston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,020 participants |
| Start Date | 2021-09-07 |
| Est. Completion | 2029-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05059444
The ClinicalTrials.gov registry entry for NCT05059444 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,020 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 654-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (209% higher). The listed sponsor is Guardant Health, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Guardant Reveal is the first listed.
NCT05059444 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT05059444 about?
NCT05059444 is a clinical study titled "ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation". The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recu...
What is the current status of trial NCT05059444?
This trial is currently recruiting. The enrollment target is 2,020 participants. The study started on 2021-09-07. Estimated completion is 2029-08.
What conditions does trial NCT05059444 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Pancreatic Adenocarcinoma, Gastric Adenocarcinoma, Invasive Breast Carcinoma, Cutaneous Melanoma.
What interventions are being tested in trial NCT05059444?
The interventions under investigation include: Guardant Reveal (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05059444?
This trial is sponsored by Guardant Health, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05059444 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.